Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis, Non−Small-cell Lung Cancer (Single-base Extension)

Casandra

Casandra Test Code LC04091Version 1 (DRAFT)

Performing Lab

Lab LabcorpLab Test ID 489360

Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis, Non−Small-cell Lung Cancer (Single-base Extension)

Also known as: Erlotinib Responsiveness in NSCLC, EGFR Mutation Analysis, Gefitinib Responsiveness in NSCLC, EGFR Mutation Analysis, IRESSA® Responsiveness in NSCLC, EGFR Mutation Analysis, Non−Small-cell Lung Cancer, EGFR Mutation, Tarceva® Responsiveness in NSCLC, EGFR Mutation Analysis

Clinical Use

Order Test

Use

In non-small cell lung cancer, many mutations in EGFR are associated with responsiveness to EGFR tyrosine kinase inhibitor (TKI) therapy. In contrast, some mutations in EGFR are associated with resistance to EGFR TKI therapy, including T790M and EGFR exon 20 insertions. The T790M mutation is a known mechanism of resistance and is commonly associated with relapse following initial therapy with EGFR TKI.

Special Instructions

Not provided.

Limitations

The EGFR test is designed to detect mutations in exon 18, 19, 20, and 21 of the EGFR gene. These mutations account for >99% of all reported EGFR mutations in NSCLC patients. Samples with results reported as "no mutation detected" may harbor EGFR mutations that are not detected by the assay.

Test Details